|
Ribavirin With or Without Monoclonal Antibody Therapy in Treating Patients Who Develop RSV Pneumonia Following Peripheral Stem Cell Transplantation Clinical Trials References presented on Clinical Trials Search isn't meant to be a substitute for proven healthcare advice, trips or professional assistance using a genuine physician. We are not docs. Always confer with your physician about Ribavirin With or Without Monoclonal Antibody Therapy in Treating Patients Who Develop RSV Pneumonia Following Peripheral Stem Cell Transplantation conditions. Clinical Trials Search.org is a site devoted to listing clinical research studies in human subjects. Ribavirin With or Without Monoclonal Antibody Therapy in Treating Patients Who Develop RSV Pneumonia Following Peripheral Stem Cell Transplantation Clinical research trials and Ribavirin With or Without Monoclonal Antibody Therapy in Treating Patients Who Develop RSV Pneumonia Following Peripheral Stem Cell Transplantation healthcare trials happen in hundreds of localities throughout the United States of America. A clinical trial or clinical study is a research project with human volunteer subjects. Clinical drug trials and pharmaceutical clinical trials usually evaluate the potency of new drugs. The propose of the studies / projects is to answer particular human health questions. Clinical trials are a popular way for mDs, government agencies, and private sector companies to detect cures for all sorts of conditions, such as Ribavirin With or Without Monoclonal Antibody Therapy in Treating Patients Who Develop RSV Pneumonia Following Peripheral Stem Cell Transplantation. Ribavirin With or Without Monoclonal Antibody Therapy in Treating Patients Who Develop RSV Pneumonia Following Peripheral Stem Cell Transplantation Clinical Trials and other clinical trials allow volunteers to acquire healthcare treatment choices before they are available to the general public. Some times the subjects recieve professional assistance for free, and every now and again they are compensated for their time. Sometimes there is a cost for a Ribavirin With or Without Monoclonal Antibody Therapy in Treating Patients Who Develop RSV Pneumonia Following Peripheral Stem Cell Transplantation clinical trial. Subjects frequently obtain the most expert healthcare possible for their Ribavirin With or Without Monoclonal Antibody Therapy in Treating Patients Who Develop RSV Pneumonia Following Peripheral Stem Cell Transplantation condition. Risks are a reality, nevertheless, and can include more or frequent doctor trips, medical risks (possibly life-threatening), and/or the treatment being uneffective. Trials are federally governed with stern guidelines to protect clinical trials patients.
|
|
|
|
|
|
|
Home > "R" Clinical Trials Conditions > Ribavirin With or Without Monoclonal Antibody Therapy in Treating Patients Who Develop RSV Pneumonia Following Peripheral Stem Cell Transplantation  Ribavirin With or Without Monoclonal Antibody Therapy in Treating Patients Who Develop RSV Pneumonia Following Peripheral Stem Cell Transplantation
Ribavirin With or Without Monoclonal Antibody Therapy in Treating Patients Who Develop RSV Pneumonia Following Peripheral Stem Cell Transplantation
For Condition: Leukemia,ovarian epithelial cancer,Testicular Cancer,Breast Cancer,Lymphoma,Multiple Myeloma,kidney tumor
Status: No longer recruiting
Sponsor(s): National Cancer Institute (NCI) , Fred Hutchinson Cancer Research Center
Synopsis: RATIONALE: Antivirals such as ribavirin are used to treat infections caused by viruses. It is not yet known if ribavirin is more effective with or without monoclonal antibody therapy in treating patients who develop RSV pneumonia following peripheral stem cell transplantation. PURPOSE: Randomized phase III trial to compare the effectiveness of ribavirin with or without monoclonal antibody in treating patients who develop RSV pneumonia following peripheral stem cell transplantation.
Details: OBJECTIVES: I. Compare the efficacy, in terms of all-cause mortality reduction, of ribavirin with or without palivizumab in patients with respiratory syncytial virus pneumonia following stem cell transplantation. II. Determine the safety of these treatments in this patient population. PROTOCOL OUTLINE: This is a randomized, double-blind, placebo-controlled, multicenter study. Patients are stratified according to prior ribavirin exposure for this infection (24 hours or more vs less than 24 hours) and requirement for ventilator support (yes vs no). Patients are randomized to one of two treatment arms. Arm I: Patients receive aerosolized ribavirin via face mask or oxygen tent over 2 hours 3 times daily or over 16-18 hours on days 1-10 and palivizumab IV 2 hours before ribavirin administration on day 1. Arm II: Patients receive aerosolized ribavirin as in arm I and placebo IV 2 hours before ribavirin administration on day 1. Patients are followed at 14, 21, and 28 days. PROJECTED ACCRUAL: A total of 140 patients (70 per arm) will be accrued for this study within 2 years.
Eligibility:
Study Type: Interventional, Educational/Counseling/Training
Minimum Age/Maximum Age: /
Genders:
Protocol Entry Criteria: PROTOCOL ENTRY CRITERIA: --Disease Characteristics-- - Confirmed respiratory syncytial virus (RSV) pneumonia documented by rapid antigen test (ELISA or IFA), shell vial culture of bronchoalveolar lavage specimens, or tissue antigen staining of lung biopsy sample; New infiltrate on chest x-ray and at least one of the following: Cough; Wheezing; Dyspnea and/or tachypnea (greater than 150% of baseline); Oxygen saturation less than 90% on two occasions 1 hour apart on room air; Arterial oxygen pressure less than 80 - No more than 60 hours since confirmation of pneumonia by chest x-ray - Received prior stem cell transplantation and meet one of the following: Between start of conditioning (preparative) regimen and day 90 after allogeneic, autologous, or syngeneic stem cell transplantation (SCT); Between days 91 and 180 after unrelated HLA mismatch-related allogeneic SCT (bone marrow, peripheral blood stem cells (PBSC), or cord blood), T-cell depleted allogeneic transplantation, or CD34 selected allogeneic PBSC transplantation; Between days 91 and 180 after SCT with graft-versus-host disease requiring systemic steroids expected to continue throughout study - Other pulmonary pathogens in addition to RSV allowed --Prior/Concurrent Therapy-- - Biologic therapy: See Disease Characteristics; At least 3 months since prior immunotherapy for respiratory syncytial virus (RSV) including RSV hyperimmune globulin or other RSV monoclonal antibodies; Concurrent IV immunoglobulin allowed; No prior experimental RSV vaccine; No concurrent RSV hyperimmune globulin; No other concurrent RSV-specific monoclonal antibodies - Chemotherapy: Not specified - Endocrine therapy: See Disease Characteristics - Radiotherapy: Not specified - Surgery: Not specified - Other: At least 4 weeks since prior investigational products for respiratory viral diseases; At least 3 months since prior anti-viral drugs with specific anti-RSV activity; Prior aerosolized ribavirin allowed; No other concurrent anti-viral drugs with specific anti-RSV activity; Concurrent ganciclovir or foscarnet allowed; Ventilator support allowed --Patient Characteristics-- - Age: Any age - Performance status: Not specified - Life expectancy: At least 48 hours - Hematopoietic: Not specified - Hepatic: Not specified - Renal: Not specified - Other: No prior adverse reaction to ribavirin or palivizumab; No allergy to monoclonal antibodies; HIV negative; Not pregnant or nursing; Negative pregnancy test; Fertile patients must use effective contraception during and for 3 months after study
Total Enrollment:
Location and Contact Information:
Overall Study Official:
MichaelBoeckh, Study Chair, Fred Hutchinson Cancer Research Center
Fred Hutchinson Cancer Research Center
Seattle, Washington, 98109
United States
Additional Information:
Study ID Numbers: CDR0000068540; NCI-G01-1929,FHCRC-1379.00
Study Start Date: February 1999
Record last reviewed: April 2004
Additional information available at: clinicaltrials.gov
Clinicaltrials.gov Reference link: NCT00014391
Other Lymphoma Studies:
1. Siplizumab in Treating Patients With Lymphoproliferative Disorder
2. Stem Cell Transplantation in Treating Patients with Hematologic Cancer
3. Peripheral Stem Cell Transplantation in Treating Patients With Breast Cancer or Hematologic Cancer
4. ZD0473 and Doxorubicin in Treating Patients With Advanced Solid Tumors or Lymphoma
5. Conventional Care With or Without Specialized Cancer Care in Treating Patients Receiving Chemotherapy
Related Studies:
Other Lymphoma Clinical Trials
Other Washington Clinical Trials
Other Seattle Clinical Trials
Ribavirin With or Without Monoclonal Antibody Therapy in Treating Patients Who Develop RSV Pneumonia Following Peripheral Stem Cell Transplantation
|
|
|
|
|
|
|
|
